KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (ONC) Return on Sales (2016 - 2025)

BeOne Medicines (ONC) has disclosed Return on Sales for 11 consecutive years, with 0.16% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales rose 30.0% to 0.16% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.09%, a 26.0% increase, with the full-year FY2025 number at 0.09%, up 26.0% from a year prior.
  • Return on Sales was 0.16% for Q4 2025 at BeOne Medicines, up from 0.09% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.28% in Q3 2023 to a low of 3.2% in Q2 2021.
  • A 5-year average of 0.79% and a median of 0.46% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: skyrocketed 712bps in 2021, then plummeted -153bps in 2022.
  • BeOne Medicines' Return on Sales stood at 2.83% in 2021, then soared by 63bps to 1.06% in 2022, then skyrocketed by 45bps to 0.58% in 2023, then skyrocketed by 77bps to 0.13% in 2024, then skyrocketed by 221bps to 0.16% in 2025.
  • Per Business Quant, the three most recent readings for ONC's Return on Sales are 0.16% (Q4 2025), 0.09% (Q3 2025), and 0.07% (Q2 2025).